Global abnormalities in lymphatic function following systemic therapy in patients with breast cancer

被引:18
作者
Bains, S. K. [1 ,2 ]
Peters, A. M. [6 ]
Zammit, C. [7 ]
Ryan, N. [6 ]
Ballinger, J. [3 ]
Glass, D. M. [4 ]
Allen, S. [3 ]
Stanton, A. W. B. [5 ]
Mortimers, P. S. [5 ]
Purushotham, A. D. [1 ,2 ]
机构
[1] Kings Coll London, Div Canc Studies, London WC2R 2LS, England
[2] Guys & St Thomas NHS Fdn Trust, Dept Breast Surg, London, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Nucl Med, London, England
[4] Harley St Clin, Mol Imaging Ctr, London, England
[5] Univ London, Clin Sci, London, England
[6] Brighton & Sussex Univ Hosp NHS Trust, Dept Nucl Med, Brighton, E Sussex, England
[7] Brighton & Sussex Univ Hosp NHS Trust, Dept Breast Surg, Brighton, E Sussex, England
关键词
RISK-FACTORS; FLUID RETENTION; ARM LYMPHEDEMA; DOCETAXEL; SURVIVORS; ADJUVANT; HEALTH; EDEMA;
D O I
10.1002/bjs.9766
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Breast cancer-related lymphoedema (BCRL) is a result of interaction between several pathophysiological processes, and is not simply a 'stopcock' effect resulting from removal of axillary lymph nodes. The aim of this study was to test the hypothesis that there is a constitutional 'global' lymphatic dysfunction in patients who develop BCRL. Methods: Lower-limb lymphoscintigraphy was performed in 30 women who had undergone axillary lymph node dissection at least 3 years previously, of whom 15 had BCRL and 15 did not. No patient had any clinical abnormality of the lower limb. The control group comprised 24 women with no history of cancer or lower-limb lymphoedema. Tc-99m-Nanocoll was injected subcutaneously into the first webspace of each foot, followed by whole-body imaging. Scans were reported as abnormal if there was delay in lymph transport or rerouting through skin or deep system. Quantification was expressed as the percentage injected activity accumulating in ilioinguinal nodes. Results: Mean(s.d.) ilioinguinal nodal accumulation at 150 min was significantly lower in women with BCRL than in those without (2.7(2.5) versus 5.9(4.8) per cent respectively; P = 0.006). Abnormal findings on lower-limb lymphoscintigraphy were observed in 17 of the 30 patients: ten of the 15 women who had BCRL and seven of the 15 who did not. None of the 24 control subjects had abnormal scan findings. Conclusion: Women with BCRL had reduced lower-limb lymph drainage, supporting the hypothesis of a predisposition to BCRL. A surprisingly high proportion of patients with breast cancer also demonstrated lymphatic dysfunction, despite clinically normal lower limbs. Possible explanations could be a systemic effect of breast cancer or its treatment, or an unidentified association between breast cancer and lymphatic dysfunction. Registration number: ISRCTN84866416 (http://www.isrctn.com).
引用
收藏
页码:534 / 540
页数:7
相关论文
共 25 条
[1]   Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study [J].
Ahmed, Rehana L. ;
Schmitz, Kathryn H. ;
Prizment, Anna E. ;
Folsom, Aaron R. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (03) :981-991
[2]   The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication [J].
Behar, A ;
PujadeLauraine, E ;
Maurel, A ;
Brun, MD ;
Lagrue, G ;
DeChauvin, FF ;
OulidAissa, D ;
Hille, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) :653-658
[3]   Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer [J].
Blanchard, DK ;
Donohue, JH ;
Reynolds, C ;
Grant, CS .
ARCHIVES OF SURGERY, 2003, 138 (05) :482-487
[4]  
Cancer Research UK, 2014, Breast cancer statistics
[5]   Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis [J].
DiSipio, Tracey ;
Rye, Sheree ;
Newman, Beth ;
Hayes, Sandi .
LANCET ONCOLOGY, 2013, 14 (06) :500-515
[6]  
Fontaine C, 2011, EUR J LYMPHOL RELATE, V22, P20
[7]   THE TAXOIDS - PACLITAXEL AND DOCETAXEL [J].
GELMON, K .
LANCET, 1994, 344 (8932) :1267-1272
[8]   Risk Factors for Lymphedema in a Prospective Breast Cancer Survivorship Study The Pathways Study [J].
Kwan, Marilyn L. ;
Darbinian, Jeanne ;
Schmitz, Kathryn H. ;
Citron, Rebecca ;
Partee, Paula ;
Kutner, Susan E. ;
Kushi, Lawrence H. .
ARCHIVES OF SURGERY, 2010, 145 (11) :1055-1063
[9]   Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. [J].
Martin, Miguel ;
Segui, Miguel A. ;
Anton, Antonio ;
Ruiz, Amparo ;
Ramos, Manuel ;
Adrover, Encarna ;
Aranda, Ignacio ;
Rodriguez-Lescure, Alvaro ;
Grosse, Regina ;
Calvo, Lourdes ;
Barnadas, Agusti ;
Isla, Dolores ;
Martinez del Prado, Purificacion ;
Ruiz Borrego, Manuel ;
Zaluski, Jerzy ;
Arcusa, Angels ;
Munoz, Montserrat ;
Lopez Vega, Jose M. ;
Mel, Jose R. ;
Munarriz, Blanca ;
Llorca, Cristina ;
Jara, Carlos ;
Alba, Emilio ;
Florian, Jesus ;
Li, Junfang ;
Lopez Garcia-Asenjo, Jose A. ;
Saez, Amparo ;
Jose Rios, Maria ;
Almenar, Sergio ;
Peiro, Gloria ;
Lluch, Ana .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23) :2200-2210
[10]   Breast cancer - Related lymphedema [J].
Morrell, RM ;
Halyard, MY ;
Schild, SE ;
Ali, MS ;
Gunderson, LL ;
Pockaj, BA .
MAYO CLINIC PROCEEDINGS, 2005, 80 (11) :1480-1484